देश: संयुक्त राज्य
भाषा: अंग्रेज़ी
स्रोत: NLM (National Library of Medicine)
OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP)
USV North America Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Acromegaly Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels (see DOSAGE AND ADMINISTRATION). In patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in
Octreotide Acetate Injection is a clear colorless sterile solution and is available in amber vials containing 1 mL of solution. NDC 76135-009-01 ; 50 mcg/mL octreotide (as acetate), carton of 10 single-dose 1 mL vials. NDC 76135-010-01 ; 100 mcg/mL octreotide (as acetate), carton of 10 single-dose 1 mL vials. NDC 76135-011-01 ; 500 mcg/mL octreotide (as acetate), carton of 10 single-dose 1 mL vials. Storage For prolonged storage, octreotide acetate injection vials should be stored at refrigerated temperatures 2° to 8°C (36° to 46°F) and protected from light. At room temperature, (20° to 30°C or 70° to 86°F), octreotide acetate injection is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. Dispose unused product or waste properly. Manufactured by: USV Private Limited H-13, 16, 16 A, 17, 18, 19, 20, 21 and E-22, OIDC, Mahatma Gandhi Udyog Nagar, Dabhel, Daman 396210, India Manufactured for: USV North America Inc. 641, Lexington Avenue, 14th Floor, New York 100 22 Issued: December 2017
Abbreviated New Drug Application
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE INJECTION, SOLUTION USV NORTH AMERICA INC. ---------- RX ONLY DESCRIPTION Octreotide Acetate Injection, a cyclic octapeptide prepared as a clear, colorless sterile solution of octreotide, acetate salt, in a buffered acetic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, USP known chemically as D-phenylalanyl-L- cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-_N_-[(1_R_,2_R_)-2-hydroxy-1-(hydroxyl methyl)propyl]-L-cysteinamide cyclic (2→7)-disulfide acetate (salt), is a long-acting octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin. Octreotide Acetate Injection is available as sterile 1 mL single-dose vials in 3 strengths, each mL containing 50 mcg, 100 mcg, or 500 mcg of octreotide acetate, USP as the active and the following inactive ingredients: glacial acetic acid USP 2 mg, sodium chloride 7 mg, sodium acetate (trihydrate) USP 2 mg, and water for injection, q.s. Glacial acetic acid USP and sodium acetate (trihydrate) USP are added to provide a buffered solution, pH range 3.9 to 4.5. The molecular weight of octreotide acetate, USP is 1019.3 (free peptide, C H N O S ) and its amino acid sequence is: CLINICAL PHARMACOLOGY Octreotide acetate exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide acetate has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide acetate substantially reduces growth hormone and/or IGF-I (somatomedin C) levels in patients पूरा दस्तावेज़ पढ़ें